METAVAC® RSV-HMPV Bivalent Vaccine
Prevention of Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) infection
Key Facts
About Vaxxel
Vaxxel is a clinical-stage biotech developing intranasal live attenuated vaccines for respiratory infections, starting with a bivalent candidate for RSV and HMPV. The company's proprietary METAVAC® platform is based on a modified, non-pathogenic HMPV strain engineered to express antigens from multiple viruses, aiming to stimulate robust mucosal and systemic immunity. With a large addressable market in pediatric and elderly populations and a differentiated intranasal delivery approach, Vaxxel is positioned to address significant unmet needs in respiratory disease prevention. The company is currently in the preclinical/process development stage, advancing its lead candidate towards clinical trials.
View full company profile